Insulinlike growth factor binding proteins

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 1, 1997, Pages 1-9

  Spagnoli, Anna ^a   Rosenfeld, Ron G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002383931     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199702000-00001     Document Type: Article

References (92)

1. Spagnoli A, Rosenfeld RG: The mechanisms by which growth hormone brings about growth. Endocrinol Metab Clin North Am 1996, 25:615-631.
2. Collett-Solberg PF, Cohen P: The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996, 25:591-614. This review provides a comprehensive discussion of the impressive development in the IGFBP field over the past years. It includes detailed discussions of the role of IGFBP proteases in modulating the affinity of IGFBPs to IGFs.
3. Swisshelm K, Ryan K, Tsuchiya K, Sager R: Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci U S A 1995, 92:4472-4476.
4. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG: Insulin-like growth factor binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996, 28:619-637. A clearly written comprehensive review of recent developments in the molecular biology and posttranslational processing of IGFBPs.
5. Powell DR, Suwanichkul A, Cubbage ML, Depaolis LA, Snuggs MB, Lee PDK: Insulin inhibits transcription of the human gene for insulin-like growth factor binding protein-1. J Biol Chem 1991, 266:18868-18876.
6. Gronowski AM, Rotwein P: Rapid changes in gene expression after in vivo growth hormone treatment. Endocrinology 1995, 136:4741-4748.
7. Luo J, Reid RE, Murphy LJ: Dexamethasone increases hepatic insulin-like growth factor binding protein-1 (IGFBP-1) mRNA and serum IGFBP-1 concentrations in the rat. Endocrinology 1990, 127:1456-1462.
8. Westwood M, Gibson JM, Davies AJ, Young RJ, White A: The phosphorylation pattern of insulin-like growth factor binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrinol Metab 1994, 79:1735-1741.
9. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR: Phosphorylation of insulin-like growth factor (IGF)-binding protein-1 in cell culture and in vivo: effects on affinity for IGF-1. Proc Natl Acad Sci U S A 1991, 88:7481-7485.
10. Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A, White A: Hormonal regulation of circulating insulin-like growth factor binding protein-1 phosphorylation status. J Clin Endocrinol Metab 1995, 80:3520-3527.
11. Lee PDK, Conover CA, Powell DR: Regulation and function of insulin-like growth factor binding protein-1. Proc Soc Exp Biol Med 1993, 204:4-29.
12. Han VKM, Bassett N, Walton J, Challis JRG: The expression of insulin-like growth factor (IGF)- and IGF-binding protein-1 (IGFBP) genes in the human placenta and membranes: evidences for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab 1996, 81:2680-2693. This paper delineates the cellular sites of expression of IGF and IGFBP mRNA in human placenta throughout pregnancy.
13. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJP, Hill DJ: Differential cellular synthesis of insulin-like growth factor binding protein-1(IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994, 79:1871-1876.
14. Nonoshita LD, Wathen NC, Dsupin BA, Chard T, Giudice LC: Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and proteolyzed IGFBP-3 in embryonic cavities in early human pregnancy, their potential relevance to maternal-embryonic and fetal interactions. J Clin Endocrinol Metab 1994, 79:1249-1255.
15. Baxter RC: Insulin-like growth factor binding proteins as glucoregulators. Metabolism 1995, 44:12-17.
16. Cohen P, Rosenfeld RG: Physiological and clinical relevance of insulin-like growth factor binding proteins. Curr Opin Pediatr 1994, 6:462-467.
17. Gibson JM, Westwood M, Young RJ, White A: Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996, 81:860-863.
18. Clemmons DR: Role of post-translational modifications in modifying the biologic activity of insulin like growth factor binding proteins. In Current Directions in Insulin-like Growth Factor Research. Edited by LeRoith D, Raizada MK. New York: Plenum Press; 1994:245-233.
19. Wojnar MM, Fan J, Frost RA, Gelato MC, Lang CH: Alterations in the insulin-like growth factor system in trauma patients. Am J Physiol (Endocrinol Metab) 1995, 268:R970-R977.
20. Frost RA, Bereket A, Wilson TA, Wojnar MM, Lang CH, Gelato MC: Phosphorylation of insulin-like growth factor binding protein-1 in patients with insulin-dependent diabetes mellitus and severe trauma. J Clin Endocrinol Metab 1994, 78:1533-1535.
21. Barrios V, Argente J, Pozo J, Hervas F, Munoz MT, Sanchez JI, Hemandez M: Insulin-like growth factor-I, insulin-like growth factor binding proteins, and growth hormone binding protein in Spanish premature and full-term newborns. Horm Res 1996, 46:130-137.
22. Giudice LC, Dezegher F, Gargosky SE, Dsupin BA, Delasfuentes L, Crystal RA, Hintz RL, Rosenfeld RG: Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995, 80:1548-1555.
23. Rajkumar K, Barron D, Lewitt MS, Murphy LJ: Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1995, 136:4029-4034. This article details the effects of IGFBP-1 overexpression in a line of transgenic mice. Mice showed reduced birth weight and demonstrated fasting hyperglycemia.
24. Bourner MJ, Busby WH, Siegel NR, Krivi GG, McCusker RH, Clemmons DR: Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2), comparison of its structural and functional properties with IGFBP-1. J Cell Biochem 1992, 48:215-226.
25. Cohen P, Noveral JP, Bhala A, Nunn SE, Herrick DJ, Grunstein MM: Leukotriene D-4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol (Lung Cellular Mol Physiol) 1995, 13:L151-L157.
26. Arai T, Busby W, Clemmons DR: Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996, 137:975-983.
27. Scharf J, Ramadori G, Braulke T, Hartmann H: Synthesis of insulin-like growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulin-like growth factor, and growth hormone. Hepatology 1996, 23:818-827.
28. Katz LEL, Rosenfeld RG, Cohen P: Clinical significance of insulin-like growth factor binding proteins proteins (IGFBPs). The Endocrinologist 1995, 5:36-43.
29. Muller HL, Oh Y, Lehrnbecher T, Blum F, Rosenfeld RG: Insulin-like growth factor binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1995, 79:428-434.
30. Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG: Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 1996, 81:150-155.
31. Bereket A, Lang CH, Blethen SL, Wilson TA: Insulin-like growth factor binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young. J Clin Endocrinol Metab 1995, 80:3647-3652.
32. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W: Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1995, 80:2700-2708. The authors characterized the importance of the ternary complex in glucoregulation. In a patient with non-islet cell tumor hypoglycemia, they reported low levels of IGFBP-3 and ALS and high levels of IGFBP-2. They hypothesized that IGFBP-2 might carry the excess of IGFs in this condition. Treatment with growth hormone and prednisolone increased IGFBP-3 and ALS and decreased IGFBP-2.
33. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M, Fujita-Yamaguchi Y: Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol 1996, 3:39-46.
34. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C: Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 1996, 81:612-617.
35. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996, 81:411-420.
36. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993, 77:229-233.
37. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfel RG: Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994, 79:1410-1415.
38. Gargosky SE, Giudice LC, Rosenfeld RG, Fazleabas AT: Different molecular and messenger ribonucleic acid forms of insulin-like growth factor binding protein-3 in the pregnant baboon (Pabio anubis). J Endocrinol 1995, 147:449-661.
39. Coverley JA, Baxter RC: Regulation of insulin-like growth factor (IGF) binding protein-3 phosphorylation by IGF-I. Endocrinology 1995, 136:5778-5781.
40. 125I-IGF-I. J Clin Endocrinol Metab 1995, 80:1318-1324.
41. Lee CY, Rechler MM: Purified acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in absence of IGFs. Endocrinology 1995, 136:4982-4989. A recent clear demonstration that in rats acid-labile subunit can form the 150-kD ternary complex in the absence of IGFs. Radiolabeled purified acid-labile subunit and recombinant human IGFBP-3 formed complexes that could be immunoprecipitated with antiserum to human IGFBP-3. However, authors showed that inclusion of IGF-I in the incubation increased the abundance of complex formation.
42. Baxter RC: Insulin-like growth factor binding proteins in the human circulation, a review. Horm Res 1994, 42:140-144.
43. Spagnoli A, Gargosky SE, Spadoni GI, McGillivray M, Oh Y, Boscherini B, Rosenfeld RG: Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy. J Clin Endocrinol Metab 1995, 80:3668-3676.
44. Mandel S, Moreland E, Nichols V, Hanna C, LaFranchi S: Changes in insulin-like growth factor binding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment. J Clin Endocrinol Metab 1995, 80:190-194.
45. Nunex SB, Municchi G, Barnes KM, Rose SR: Insulin-like growth factor (IGF-I) and IGF-binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children. A clinical research center study. J Clin Endocrinol Metab 1996, 81:1927-1932. The most recent paper that demonstrates the usefulness of IGF-I and IGFBP-3 as screening tests for the diagnosis of growth hormone deficiency. Authors showed that combined screening for growth hormone deficiency has no better sensitivity than either test alone. However, combined screening improves the specificity and thus decrease the number of normal children that might undergo unnecessary growth hormone testing.
46. Cianfarani S, Boemi S, Spagnoli A, Cappa M, Argiro G, Vaccaro F, Manca-Bitti ML, Boscherini B: Is IGF binding protein-3 assessment helpful for the diagnosis of GH deficiency? Clin Endocrinol 1995, 43:43-47.
47. Crawford BA, Handelsman DJ: Androgens regulate circulating levels of insulin-like growth factor (IGF-I) and IGF-binding protein-3 during puberty in male baboons. J Clin Endocrinol Metab 1996, 81:65-72. A pertinent report that shows the regulation of IGFBP-3 by androgens. In male primates, serum IGF-I and IGFBP-3 increased during puberty, but castrated animals had no rise in IGF-I and IGFBP-3 levels. Testosterone administration resulted in a near normalization of the IGF axis.
48. Juul A, Scheike T, Nielsen CT, Krabbe S, Muller J, Skakkebaek NE: Serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate). J Clin Endocrinol Metab 1995, 80:3059-3067.
49. Valez-Yanguas MC, Kalebic T, Maggi M, Kappel CC, Letterio J, Uskokovic M, Helman LJ: 25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J Clin Endocrinol Metab 1996, 81:93-99.
50. Moriwake T, Abribat T, Brazeau P, Ecarot B: Serum insulin-like growth factor binding protein-3 in the hyposphatemic mouse: decreased activity and abnormal modulation by dietary phosphate. J Bone Min Res 1995, 10:1698-1704.
51. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 1993, 7:380-386.
52. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995, 93:361-367.
53. Oh Y, Muller HL, Pham HM, Rosenfeld RG: Demonstration of receptors for insulin-like growth factor binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993, 268:14964-14971.
54. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG: Insulin-like growth factor binding protein-3 mediates retinoic acid- and transforming growth factor beta-2-induced growth inhibition in human breast cancer cells. Cancer Res 1996, 56:1545-1550.
55. Oh Y, Muller HL, Ng L, Rosenfeld RG: Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor binding protein-3 action. J Biol Chem 1995, 270:13589-13592.
56. Hung H, Yang X, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein-3 autocrine loop in human breast cancer cells. J Biol Chem 1996, 271:1016-1021.
57. Bruning PF, Van Doom J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA: Insulin-like growth factor binding protein-3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995, 62:266-270.
58. Buckbinder L, Talbott R, Velasco-Miguel S, Takenada I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649. Using DNA cloning approach, these authors have identified IGFBP-3 as a novel target of p53. Model used was a cell line transfected with inducible wild-type p53 gene under control of metallothionein promoter. Activation of p53 transgene in this cell line led to apoptosis. Authors showed stimulation of IGFBP-3 mRNA levels after p53 induction. They found two p53 binding sites in the sequence of IGFBP-3. Study findings suggest an important role of IGFBP-3 in p53 regulation of cell growth.
59. Frost RA, Nachman SA, Lang CH, Gelato MC: Proteolysis of insulin-like growth factor binding protein-3 in human immunodeficiency virus-positive children who fall to thrive. J Clin Endocrinol Metab 1996, 81:2957-2962.
60. Lee GY, Rechler MM: Proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in 150-kilodalton IGFBP complexes by a cation-dependent protease activity in adult rat serum promotes the release of bound IGF-I. Endocrinology 1996, 137:2051-2058.
61. Spagnoli A, Chiarelli, Boemi S, Germani D, Boscherini B, Rosenfeld RG: Is the insulin-like growth factor binding protein-3 a marker of insulin dependent diabetic microalbuminuria? Program and Abstracts of the 10th International Congress of Endocrinology, San Francisco. June 1996, OR59-4,735.
62. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992, 75:1046-1053.
63. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG: Biological effects of prostate specific antigen as an insulin-growth factor binding protein-3 protease. J Endocrinol 1994, 142:407-415.
64. Lalou C, Lassarre C, Binoux M: A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996, 137:3206-3212.
65. Booth BA, Boes M, Bar RS: IGFBP-3 proteolysis by plasmin, thrombin, serum. Heparin binding, IGF binding, and structure of fragments. Am J Physiol (Endocrinol Metab) 1996, 34:E465-E470.
66. Fowlkes JL, Serra DM: Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor binding protein-3. J Biol Chem 1996, 271:14676-14679.
67. Hasegawa T, Cohen P, Rosenfeld RG: Characterization of the insulin-like growth factor axis in TM 3 Leydig cells. Growth Regul 1995, 5:151-159.
68. Honda Y, Landale EC, Strong DD, Baylink DJ, Mohan S: Recombinant synthesis of insulin-like growth factor binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. J Clin Endocrinol Metab 1996, 81:1389-1396. This paper reports the development of a radioimmunoassay for IGFBP-4, IGFBP-4 serum levels were determined, and higher levels were found in older subjects. IGFBP-4 showed a positive correlation with age and serum parathyroid hormone levels. Data indicate the involvement of IGFBP-4 in bone metabolism and aging process.
69. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ: Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 1995, 270:20424-20431. This study demonstrates that IGFBP-4 and IGFBP-5 exhibit opposite effects on bone cell proliferation. IGFBP-4 decreases the binding of iodinated IGFs to receptor. In contrast, IGFBP-5 increased the receptor binding of IGF peptides. The authors also indicated a IGFBP-5 cell surface binding independent of IGF receptor. Based on these findings, they proposed a model to explain IGFBP-4 and -5 actions. They hypothesized that IGFBP-4 might inhibit IGF binding to the receptor by binding to IGFs near the receptor site, while IGFBP-5 binding to the cell surface could facilitate delivery of IGFs to the receptor.
70. Conover CA, Kiefer MC, Zapf J: Posttranslational regulation of insulin-like growth factor binding protein-4 in human osteoblastic cells. J Clin Endocrinol Metab 1993, 91:1129-1137.
71. Fowlkes JL, Serra DM, Rosenberg CK, Thraikill KM: Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis. J Biol Chem 1995, 270:27481-27488.
72. Donnelly MJ, Holly JM: The role of IGFBP-3 in the regulation of IGFBP-4 proteolysis. J Endocrinol 1996, 149:R1-R7.
73. Torring O, Firek AF, Health H, Conover CA: Parathyroid hormone and parathyroid hormone-related peptide stimulated insulin-like growth factor binding protein secretion by rat osteoblast-like cells through adenosine 3′,5′-monophophate-dependent mechanism. Endocrinology 1991, 128:1006-1014.
74. Kudo Y, Iwashita M, Itatsu S, Iguchi T, Takeda Y: Regulation of insulin-like growth factor binding protein-4 protease activity by estrogen and parathyroid hormone in SaOS-2 cells. Implications for the pathogenesis of postmenopausal osteoporosis. J Endocrinol 1996, 150:223-229.
75. Parker A, Clarke JB, Busby WH, Clemmons RD: Identification of the extracellular matrix binding sites for insulin-like growth factor binding protein 5. J Biol Chem 1996, 271:13523-13529.
76. Arai T, Clarke J, Parker A, Busby W Jr, Nam T, Clemmons DR: Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J Biol Chem 1996, 271:6099-6106.
77. Mohan S, Libanati C, Dony C, Lang K, Srinivasan N, Baylink DJ: Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab 1995, 80:2638-2645.
78. Jones JI, Gockerman A, Busby WHJ, Camacho-Hubner C, Clemmons DR: Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Biol Chem 1993, 121:679-687.
79. Duan C, Hawes SB, Prevette T, Clemmons: Insulin-like growth factor (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J Biol Chem 1996, 271:4280-4288.
80. Andress DL: Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem 1995, 270:28289-282896.
81. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins, biological actions. Endocr Rev 1995, 16:3-34.
82. Adashi EY: Regulation of intrafollicular IGFBPs, possible relevance to ovarian follicular selection. In The Insulin-like Growth Factors and Their Regulatory Protein. Edited by Baxter RC, Gluckman PD, Rosenfeld RG. Amsterdam; Elsevier; 1994:341-350.
83. Ramacle-Bonnet M, Garrouste F, el-Atiqu F, Marvaldi J, Pommier G: Cell polarity of the insulin-like growth factor system in human intestinal epithelial cells. Unique apical sorting of insulin-like growth factor binding protein-6 in differentiated human colon cancer cells. J Biol Chem 1995, 96:192-200.
84. Bach LA, Salemi R, Leeding KS: Roles of insulin-like growth factor (IGF) receptors and IGF-binding proteins in IGF-II induced proliferation and differentiation of L6A1 rat myoblats. Endocrinology 1995, 136:5061-5069.
85. Bach LA, Thotakura NR, Rechler MM: Human insulin-like growth factor binding protein-6 is O-glycosylated. Growth Regul 1993, 3:59-62.
86. Gabbitas B, Canalis E: Cortisol enhances the transcription of insulin-like growth factor binding protein-6 in cultured osteoblasts. Endocrinology 1996, 137:1687-1692.
87. Claussen M, Buergisser D, Schuller AG, Metzner U, Braulke T: Regulation of insulin-like growth factor (IGF)-binding protein-6 and mannose 6-phosphate/IGF-II receptor expression in IGF-IL-overexpressing NIH 3T3 cells. Mol Endocrinol 1995, 9:902-912.
88. Zhou Y, Mohan S, Linkhart TA, Baylink DJ, Strong DD: Retinoic acid regulates insulin-like growth factor binding protein expression in human osteoblast cells. Endocrinology 1996, 137:975-983.
89. Rohan RM, Ricciarelli E, Kiefer MC, Resnick CE, Adashi EY: Rat ovarian insulin-like growth factor binding protein-6: a hormonally regulated theca-interstitial-selective species with limited antigonadotropic activity. Endocrinology 1993, 132:2507-2512.
90. Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson EM, Rosenfeld RG: Synthesis and characterization of insulin-like growth factor binding protein (IGFBP)-7. J Biol Chem 1996, 271:30322-30325. This paper describes the characterization of a novel IGFBP named IGFBP-7.
91. Wilson EM, Oh Y, Rosenfeld RG: Generation and characterization of IGFBP-7 antibodies: Identification of 31 kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab 1996, submitted.
92. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL: Identification and characterization of genes differentially expressed in meninglomas. Cell Growth Differ 1993, 4:715-722.